MX2021005453A - Tratamiento de combinacion para hipertension resistente. - Google Patents
Tratamiento de combinacion para hipertension resistente.Info
- Publication number
- MX2021005453A MX2021005453A MX2021005453A MX2021005453A MX2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A
- Authority
- MX
- Mexico
- Prior art keywords
- combination treatment
- resistant hypertension
- hypertension
- combination
- resistant
- Prior art date
Links
- 208000015658 resistant hypertension Diseases 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229960003883 furosemide Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758009P | 2018-11-09 | 2018-11-09 | |
| PCT/US2019/060401 WO2020097421A1 (en) | 2018-11-09 | 2019-11-08 | Combination treatment for resistant hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005453A true MX2021005453A (es) | 2021-09-08 |
Family
ID=70612496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005453A MX2021005453A (es) | 2018-11-09 | 2019-11-08 | Tratamiento de combinacion para hipertension resistente. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220118054A1 (https=) |
| EP (2) | EP4603090A1 (https=) |
| JP (2) | JP2022506716A (https=) |
| KR (1) | KR20210090229A (https=) |
| CN (1) | CN113727997A (https=) |
| AU (2) | AU2019375988A1 (https=) |
| BR (1) | BR112021008841A2 (https=) |
| CA (1) | CA3119055A1 (https=) |
| ES (1) | ES3047085T3 (https=) |
| IL (2) | IL282958B2 (https=) |
| MX (1) | MX2021005453A (https=) |
| PL (1) | PL3877402T3 (https=) |
| WO (1) | WO2020097421A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240369535A1 (en) * | 2021-09-07 | 2024-11-07 | Mayo Foundation For Medical Education And Research | METHODS AND MATERIALS FOR DETERMINING pGC TARGET DOSAGE |
| WO2023039453A2 (en) * | 2021-09-09 | 2023-03-16 | Mayo Foundation For Medical Education And Research | Dual-function polypeptides and methods for use thereof |
| US20240116990A1 (en) * | 2022-09-19 | 2024-04-11 | Mayo Foundation For Medical Education And Research | Compositions and Methods of Treatment Using CRRL 191 |
| KR20250150650A (ko) * | 2023-02-22 | 2025-10-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Manp를 이용한 대사증후군을 동반한 고혈압 치료 방법 |
| US12427185B2 (en) | 2023-09-05 | 2025-09-30 | E-Star Biotech, LLC | Formulations of MANP and uses thereof |
| WO2025184377A1 (en) * | 2024-02-28 | 2025-09-04 | Mayo Foundation For Medical Education And Research | Methods for sustained lowering of blood pressure using manp |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4161521A (en) | 1975-08-08 | 1979-07-17 | Merck & Co., Inc. | Somatostatin analogs |
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US4757048A (en) | 1985-11-05 | 1988-07-12 | Biotechnology Research Associates J.V. | Synthetic analogs of atrial natriuretic peptides |
| US6312679B1 (en) | 1986-08-18 | 2001-11-06 | The Dow Chemical Company | Dense star polymer conjugates as dyes |
| US4935492A (en) | 1987-12-24 | 1990-06-19 | California Biotechnology Inc. | Cyclic analogs of atrial natriuretic peptides |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE4004430A1 (de) | 1990-02-09 | 1991-08-14 | Schering Ag | Aus polyaldehyden aufgebaute kontrastmittel |
| KR930009516B1 (ko) | 1990-04-27 | 1993-10-06 | 미쓰비시덴키 가부시키가이샤 | 진동검출기 및 그의 고유진동주파수 조정방법 |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5698213A (en) | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
| US6410044B1 (en) | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
| US6969480B2 (en) | 2000-05-12 | 2005-11-29 | Matregen Corp. | Method of producing structures using centrifugal forces |
| WO2004047871A2 (en) | 2002-11-26 | 2004-06-10 | Nobex Corporation | Modified naturetic compounds, conjugates, and uses thereof |
| DE602005013244D1 (de) | 2004-08-12 | 2009-04-23 | Quest Pharmaceutical Services | Pharmazeutische zusammensetzungen für die kontroll |
| WO2008061355A1 (en) | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
| US20100266704A1 (en) | 2008-12-15 | 2010-10-21 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
| WO2015135024A1 (en) * | 2014-03-14 | 2015-09-17 | Madeleine Pharmaceuticals Pty Ltd | Adjuvant therapy to standard of care (soc) diuretic treatment |
| US11072642B2 (en) * | 2016-11-09 | 2021-07-27 | Mayo Foundation For Medical Education And Research | MANP analogues |
-
2019
- 2019-11-08 PL PL19881216.6T patent/PL3877402T3/pl unknown
- 2019-11-08 IL IL282958A patent/IL282958B2/en unknown
- 2019-11-08 ES ES19881216T patent/ES3047085T3/es active Active
- 2019-11-08 CN CN201980088279.4A patent/CN113727997A/zh active Pending
- 2019-11-08 CA CA3119055A patent/CA3119055A1/en active Pending
- 2019-11-08 KR KR1020217017589A patent/KR20210090229A/ko not_active Ceased
- 2019-11-08 US US17/292,083 patent/US20220118054A1/en not_active Abandoned
- 2019-11-08 WO PCT/US2019/060401 patent/WO2020097421A1/en not_active Ceased
- 2019-11-08 BR BR112021008841-5A patent/BR112021008841A2/pt unknown
- 2019-11-08 IL IL315007A patent/IL315007A/en unknown
- 2019-11-08 EP EP25186872.5A patent/EP4603090A1/en active Pending
- 2019-11-08 JP JP2021524278A patent/JP2022506716A/ja active Pending
- 2019-11-08 EP EP19881216.6A patent/EP3877402B1/en active Active
- 2019-11-08 AU AU2019375988A patent/AU2019375988A1/en not_active Abandoned
- 2019-11-08 MX MX2021005453A patent/MX2021005453A/es unknown
-
2024
- 2024-07-11 JP JP2024111406A patent/JP2024156691A/ja active Pending
-
2025
- 2025-04-29 US US19/193,423 patent/US20250381249A1/en active Pending
- 2025-05-16 AU AU2025203575A patent/AU2025203575A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL282958B2 (en) | 2025-01-01 |
| US20250381249A1 (en) | 2025-12-18 |
| KR20210090229A (ko) | 2021-07-19 |
| AU2019375988A1 (en) | 2021-05-27 |
| IL315007A (en) | 2024-10-01 |
| EP3877402B1 (en) | 2025-07-16 |
| WO2020097421A1 (en) | 2020-05-14 |
| CA3119055A1 (en) | 2020-05-14 |
| IL282958B1 (en) | 2024-09-01 |
| EP3877402A1 (en) | 2021-09-15 |
| ES3047085T3 (en) | 2025-12-03 |
| JP2022506716A (ja) | 2022-01-17 |
| EP3877402A4 (en) | 2022-07-27 |
| JP2024156691A (ja) | 2024-11-06 |
| CN113727997A (zh) | 2021-11-30 |
| PL3877402T3 (pl) | 2025-12-01 |
| IL282958A (en) | 2021-06-30 |
| BR112021008841A2 (pt) | 2021-08-31 |
| AU2025203575A1 (en) | 2025-06-05 |
| EP4603090A1 (en) | 2025-08-20 |
| US20220118054A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005453A (es) | Tratamiento de combinacion para hipertension resistente. | |
| CO2018013104A2 (es) | Polipéptidos de fusión cd40l-fc y sus métodos de uso | |
| MY199751A (en) | Anti-igf-i receptor antibody | |
| MY194032A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
| WO2020061229A3 (en) | Arc-based capsids and uses thereof | |
| UY37834A (es) | Tratamiento de mh con compuestos de pirimidinadiona | |
| EA202190822A1 (ru) | Технологии для выполнения действий на основе обнаружения объектов | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| UY37576A (es) | Anticuerpos dirigidos a hueso | |
| PE20230381A1 (es) | Proteina de union a rgma | |
| MX2022001027A (es) | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. | |
| MX2020013214A (es) | Actualizacion de graficos ejecutables. | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
| WO2020092672A3 (en) | A quantitative algorithm for endometriosis | |
| EP4374915A3 (en) | Compositions for the treatment of hypertension | |
| MX2020013722A (es) | Anticuerpos que comprenden polipeptido insertado en la region de marco 3. | |
| MX384037B (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
| MX2020003644A (es) | Metodo de martillado de union soldada con filete a solape y estructuras soldadas. | |
| UY38385A (es) | Concentrado y aislado de cannabinoide, método para su obtención y uso | |
| MX2025000236A (es) | Composiciones para el tratamiento de hipertension | |
| Ljubenović | Weak majorization and doubly substochastic operators on ℓp (I) | |
| CO2025015637A2 (es) | Quinoxalinas sustituidas | |
| CR20210244A (es) | Combinación herbicida |